Special attention has also been given to antiphospholipid antibodies (aPLs) after they were reported in severe COVID-19 patients, who had findings of the presence of anticardiolipin IgA antibodies, anti-β2-glycoprotein I IgA antibodies and anti-β2-glycoprotein IgG antibodies [16]. This evidence concerns the gene CD79A and COVID-19.